乳腔镜腋窝气腔建立及其CO_2气腔的安全性研究
|
摘要
目的:通过猪乳腔镜腋窝气腔的建立探讨其可操作性;通过建立模拟CO_2气腔探讨其对乳腺癌细胞的影响。方法:在猪上建立腋窝CO_2气腔,分析术中猪机体血气变化及电镜检测超声刀对神经超微结构的影响;体外建立模拟CO_2气腔,应用FCM、RT-PCR等方法检测其对乳腺癌细胞生长、凋亡以及对癌细胞黏附力、黏附分子ICAM-1、CD44v6表达的影响。结果:基于脂肪抽吸的乳腔镜能快速安全地建立腋窝CO_2气腔;CO_2气腔对猪机体血气的影响在可适应范围内;超声刀对神经的超微结构无显著影响;体外模拟CO_2气腔随着压力增高可抑制乳腺癌细胞生长、促进凋亡、Fas/Fas-L表达增加以及使癌细胞黏附力和黏附分子ICAM-1、CD44v6表达增高。结论:乳腔镜在动物猪上操作切实安全可行;较高分压的腋窝CO_2气腔引起乳腺癌细胞凋亡,但同时可引发免疫逃逸,并促使癌细胞侵袭力增加,应该引起乳腺外科的重视。
Objective: To investigate the feasible of mastoscopy on swine by building an air cavity of axillary fossa and the effect of an artificial CO_2 cavity on breast cancer cells. Methods: A CO_2 cavity of porcine armpit was built, then the arterial blood gas of swine was measured and the effect of UHS on ultrastructure of nerve was measured. With an artificial CO_2 cavity model in vitro, cell growth, cell apoptosis, cell adhesive power and ICAM-1, CD44v6 were measured by FCM and RT-PCR et al. Results: The CO_2 cavity can be built safely and quickly through liposuction. The effect of CO_2 cavity on porcine arterial blood gas was at range of organism adaptation. There was no significant effect of USH on neural ultrastructure. As the pressure increasing, the artificial CO_2 cavity can inhibit the growth of breast cancer cells, urge them to apoptosis, increase the expression of Fas/Fas-L, and the cell adhesive powe, the expression of ICAM-1 and CD44v6 were increased. Conclusion: The mastoscopy on swine is feasible and safe. More pressure of CO_2 cavity can cause breast cancer cells to apoptosis, immune escape and increase invasiveness of them, which should be thinked highly of by mammary surgery.
Objective: To investigate the feasible of mastoscopy on swine by building an air cavity of axillary fossa and the effect of an artificial CO_2 cavity on breast cancer cells. Methods: A CO_2 cavity of porcine armpit was built, then the arterial blood gas of swine was measured and the effect of UHS on ultrastructure of nerve was measured. With an artificial CO_2 cavity model in vitro, cell growth, cell apoptosis, cell adhesive power and ICAM-1, CD44v6 were measured by FCM and RT-PCR et al. Results: The CO_2 cavity can be built safely and quickly through liposuction. The effect of CO_2 cavity on porcine arterial blood gas was at range of organism adaptation. There was no significant effect of USH on neural ultrastructure. As the pressure increasing, the artificial CO_2 cavity can inhibit the growth of breast cancer cells, urge them to apoptosis, increase the expression of Fas/Fas-L, and the cell adhesive powe, the expression of ICAM-1 and CD44v6 were increased. Conclusion: The mastoscopy on swine is feasible and safe. More pressure of CO_2 cavity can cause breast cancer cells to apoptosis, immune escape and increase invasiveness of them, which should be thinked highly of by mammary surgery.
引文
1. Vlastos G, Verkooijen HM. Minimally invasive approaches for diagnosis and treatment of early-stage breast cancer. Oncologist, 2007, 12(1): 1-10.
2. Hall-Craggs MA, Vaidya Js. Minimally invasive therapy for the treatment of breast tumours. Eur J Radiol, 2002, 42(1):52-57.
3. Singletary SE, Fornage BD, Sneige N, et al. Radiofrequency ablation of early-stage invasive breast tumors: an overview. Cancer J, 2002, 8(2): 177-180. Review.
4.骆成玉, 季晓昕, 张键等.乳腔镜腋窝淋巴结清扫的手术技术.中华外科杂志, 2005, 43(1): 21-24.
5.张嘉庆, 王殊.乳腺外科新技术的发展与展望. 中国普外基础与临床杂志, 2005,12(3):201-203.
6. Wilmot C, Watemberg S, Landau O, et al. Of balloon axilloscopy and avoidance of iatrogenic injury to the long thoracic nerve. Arch Surg, 1997, 132(10): 1121-1124.
7. Ishizuka B, Kudo Y, Amemiya A, et al. Plasma catecholamine responses during laparoscopic gynecologic surgery with CO_2 insufflation. J Am Assoc Gynecol Laparosc, 2000, 7(1): 37-43.
8. Ordemann J, Hoflich C, Braumann C, et al. Impact of pneumoperitoneum on expression of E-cadherin, CD44v6 and CD54 (ICAM-1) on HT-29 colon-carcinoma cell. Zentralbl Chir, 2005, 130(5): 405-409.
9. Kim ZG, Mehl C, Lorenz M, et al.Impact of laparoscopic CO_2-insufflation on tumor-associated molecules in cultured colorectal cancer cells. Surg Endosc, 2002, 16(8): 1182-6.
10.王强, 章建全, 蔡清萍.实时超声引导、监测下经皮微创旋切手术治疗乳房良性肿块. 外科理论与实践, 2005, 10(1): 104-105.
1.骆成玉, 季晓昕, 张键等.乳腔镜腋窝淋巴结清扫的手术技术.中华外科杂志, 2005, 43(1): 21-24.
2.Abu-Rafea B, Vilos GA, Vilos AG, et al. High-pressure laparoscopic entry does not adversely affect cardiopulmonary function in healthy women. J Minim Invasive Gynecol, 2005, 12(6): 475-479.
3.Stang CM, Hachenberg T. Is the pneumoperitoneum minimally invasive during laparoscopic colonic surgery? Zentralbl Chir, 2004, 129(3): 196-9.
4. Mottura AA. Tumescent technique for liposuction.Plast Reconstr Surg, 1994, 94(7): 1096-1097.
5.Brown SA, Lipschitz AH, Kenkel JM, et al. Pharmacokinetics and safety of epinephrine use in liposuction. Plast Reconstr Surg, 2004, 114(3):756-763; discussion 764-765.
6.Platt MS, Kohler LJ, Ruiz R, et al. Deaths associated with liposuction: case reports and review of the literature. J Forensic Sci, 2002, 47(1):205-207.
7.Suzanne F, Emering C, Wattienz A, et al. Axillary lymphadenectomy by lipo-aspiration and endoscopic picking. Apropos of 72 cases. Chirurgie, 1997, 122(2): 138-142.
8.Salvat J, Knopf JF, Ayoubi JM. Endoscopic exploration and lymph node sampling of the axilla. Preliminary findings of a randomized pilot study comparing clinical and anatomo-pathologic results of endoscopic axillary lymph node sampling with traditional surgical treatmen.Eur J Obstet Gynecol Reprod Biol, 1996, 70(2): 165-173.
9.Kamprath S, Bechler J, Kuhne-Heid R, et al. Endoscopic axillary lymphadenectomy without prior liposuction. Development of a technique and initial experience.Surg Endosc, 1999, 13(12): 1226-1229.
10.杭燕南, 主编. 当代麻醉学. 上海: 上海科学技术出版社, 2002, 877-886.
11.Bellantone R, Lombardi CP, Rubino F, et a1. Arterial PCO2 and cardiovascular function during endoscopic neck surgery with carbon dioxide insufflation.Arch Surg, 2001, 136(7): 822-827.
12. 晋云, 陈训如. 二氧化碳气腹对呼吸循环系统影响研究的新进展. 解放军医学杂志, 2002, 7: 647-648.
13.McIntyre RC Jr, Haenel JB, Moore FA, et a1.Cardiopulmonary effects of permissive hypercapnia in the management of adult respiratory distress syndrome. J Trauma, 1994, 37(3): 433-438.
14.Naude GP Bongard FS.Helium insufflation in laparoscopic surgery. Endose Surg Allied Technol, 1995, 3(4): 183-186.
15.Bongard FS, Pianim NA, Leighton TA et a1.Helium insufflation for laparoscopic operation. Surg Gyneco, 1993, 177(2): 140-145.
16.Cakan A, Cagirici U, Cikirikcioglu M, et a1.The histological effect of harmonic scalpel and electrocautery in lung resections.An experimental study in a rat model. J Cardiovasc Surg (Torino), 2004, 45(1): 63-65.
17.Epstein MR, Mayer JE Jr, Duncan BW.Use of an ultrasonic scalpel as an alternative to electrocautery in patients with pacemakers. Ann Thorac Surg, 1998, 65(6): 1802-1804.
18.Amaral JF.The experimental development of an ultrasonically activated scalpel for laparoscopic use. Surg Laparosc Endosc, 1996, 4(2): 92-99.
19. Swanstrom LL, Pennings JL.Laparoscopic control of short gastric vessels. J Am Coll Surg, l995, 181(4): 347-351.
20.Lumachi F, Burelli P, Basso SM, et al. Usefulness of ultrasound scissors in reducing serous drainage after axillary dissection for breast cancer: a prospective randomized clinical study. Am Surg, 2004, 70(1): 80-84.
21.Porter KA, O’Connor S, Rimm E, et al. Electrocautery as a factor in seroma formation following mastectomy. Am J Surg, 1998, 176(1): 8-11.
22.Epstein MR, Mayer JE Jr, Duncan BW.Use of an ultrasonic scalpel as an alternative to electrocautery in patients with pacemakers. Ann Thorac Surg, 1998, 65(6): 1802-1804.
23.Kuhn T, Santjohanser C, Koretz K, et al. Axilloscopy and endoscopic sentinel node detection in breast cancer patients. Surg Endosc, 2000, 14(6):573-577.
24.Developments in minimally invasive breast surgery-overview and our own experience: new diagnostic and therapeutic challenges in breast cancer. Gynakol Geburtshilfliche Rundsch, 2000, 40(1): 3-12.
1.Fondrinier E, Boisdron-Celle M, Chassevent A, et al. Experimental assessment of tumor growth and dissemination of a microscopic peritoneal carcinomatosis after CO_2 peritoneal insufflation or laparotomy. Sury Endosc, 2001, 15(8): 843-848.
2.Tominaga H, Ishiyama M, Ohseto F, et al.A water-soluble tetrazolium salt useful for colorimetric cell viability assay. Anal Commun, 1999, 36(2):47-50.
3.Petersen OW, Ronnov-Jessen L, Weaver VM, et al. Differentiation and cancer in the mammary gland: shedding light on an old dichotomy. Adv Cancer Res, 1998, 75: 135-61.
4.Thompson CB.Apoptosis in pathogenesis and treatment of disease. Science, 1995, 267(5203): 1456-1462.
5.Tamm I, Schriever F, Dorken B. Apoptosis: implications of basic research for clinical oncology. Lancet Oncol, 2001, 2(1): 33-42.
6.keane MM, Ettenberg SA, Lowrey GA, et al. Fas expression and function in normal and malignant breast cell lines. Cancer Res, 1996, 56(20): 4791-4798.
7.Shrode LD, Tapper H, Grinstein, et al. Role of intracellular pH in proliferation, transformation, and apoptosis. J Bioenerg Biomember, 1997, 29(4): 393-399.
8.Lagadic-Gossmann D, Huc L, Lecureur V. Alterations of intracellular pH homeostasis in apoptosis: origins and roles. Cell Death Differ, 2004, 11(9): 953-961.
9.Jacobi CA, Sabat R, Bohm B, et al. Pneumoperitoneum with carbon dioxide stimulates growth of malignant colonic cells. Surgery, 1997, 121(1): 72-78.
10.Smidt VJ, Singh DM, Hurteau JA, et al. Effect of carbon dioxide on human ovarian carcinoma cell growth. Am J Obstet Gyneco1, 2001,185(6): 1314-1317.
11.Zhong H, De Marzo AM, Laughner E, et a1. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res, 1999, 59(22): 5830-5835.
12.Garayoa M, Martinez A, Lee S, et a1. Hypoxia-inducible factor-1 (HIF-1) up-regulates adrenomedullin expression in human tumor cell lines during oxygen deprivation: a possible promotion mechanism of carcinogenesis. Mol Endocrinol,2000, 14(6): 848-862.
13.Tendler DS, Bao C, Wang T, et a1. Intersection of interferon and hypoxia signal transduction pathways in nitric oxide-induced tumor apoptosis.Cancer Res, 2001, 61(9): 3682-3688.
14.Harmey JH, Bouchier-Hayes D. Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy. BioEssays, 2002, 24(3): 280-283.
15.左仲, 鲁向明. 乳腺癌与Fas系统. 世界肿瘤杂志, 2004,3(3): 29l-293.
16.Schett G, Steiner CW, Groger M, et a1. Activation of Fas inhibits heat-induced activation of HSF1 and up-regulation of hsp70. FASEB J,1999, 13(8): 833-842.
17.von Reyher U, Strater J, Kittstein W, et al. Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis. Cancer Res , 1998 ,58(3):526-534.
18.Nambu Y, Hughes SJ, Rehemtulla A, et al. Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas. J Clin Invest, 1998, 101(5): 1102-1110.
19.Reimer T, Herrnring C, Koczan D,et al. FasL:Fas ratio--a prognostic factor in breast carcinomas. Cancer Res, 2000, 60(4): 822-828.
20.Mottolese M, Buglioni S, Bracalenti C, et a1. Prognostic relevance of altered Fas (CD95)-system in human breast cancer.Int J Cancer, 2000, 89(2): 127-132.
21.Botti C, Buglioni S, Benevolo M, et a1. Altered expression of FAS system is related to adverse clinical outcome in stage I-II breast cancer patients treated with adjuvant anthracycline-based chemotherapy. Clin Cancer Res, 2004, 10(4): 1360-1365.
22.Sheard MA, Vojtesek B, Janakova L, et a1. Up-regulation of Fas (CD95) in human p53wild-type cancer cells treated with ionizing radiation. Int J Cancer, 1997, 73(5): 757-762.
23.Danforth DN, Zhu Y. Conversion of Fas-resistant to Fas-sensitive MCF-7 breast cancer cells by the synergistic interaction of interferon-gamma and all-trans retinoic acid. Breast Cancer Res Treat, 2005, 94(1):81-91.
24.O’Connell J, Bennett MW, O'Sullivan GC, et al.The Fas counterattack: cancer as asite of immune privilege. Immunol Today, 1999, 20(1): 46-52.
25.Shiraki K, Tsuji N, Shioda T, et al. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci USA, 1997, 94(12): 6420-6425.
26.Eberl LP, Valdenaire O, Saintgiorgio V, et al. Endothelin receptor blockade potentiates FasL-induced apoptosis in rat colon carcinoma cells. Int J Cancer, 2000, 86(2): 182-187.
27.Mullauer L, Mosberger I, Grusch M et al. Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer. J Pathol, 2000,
190(1):20-30.
28.Cianga C, ianga P, Cozma L, et al.The significance of Fas/FasL molecular system in breast cancer. Rev Med Chir Soc Med Nat Iasi, 2004, 108(2): 440-444.
29.O'Connell J, Bennett MW, O’sullivan, et al. Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege. Clin Diagn Lab Immunol, 1999, 6(4): 457-463.
30.Muller M, Wilder S, Bannasch D, et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med, 1998, 188(11): 2033-2045.
31.Muschen M, Moers C, Warskulat U, et al. CD95 ligand expression as a mechanism of immune escape in breast cancer. Immunology, 2000, 99(1): 69-77.
32.Nagarkatti N, Davis BA. Tamoxifen induces apoptosis in Fas+ tumor cells by upregulating the expression of Fas ligand. Cancer Chemother Pharmacol, 2003, 51(4): 284-290.
33.Samli MM, Guler C, Demirbas M, et al.The effect of carbon dioxide pneumoretroperitoneum on free oxygen radicals in rabbit retroperitoneoscopy model. Surg Laparosc Endosc Percutan Tech.2004, 14(3): 153-6.
1.高进.癌的侵袭与转移. 第1版.北京: 北京医科大学, 中国协和医科大学联合出版社, 1996: 17-18.
2.Gulubova MV.Expression of cell adhesion molecules, their ligands and tumour necrosis factor alpha in the liver of patients with metastatic gastrointestinal carcinomas. Histochem J, 2002, 34(1-2): 67-77.
3.Polverini PJ. Cellular adhesion molecules. Newly identified mediators of angiogenesis. Am J Patho, 1996, 148(4): 1023-1029.
4.Sunami T, Yashiro M, Chung KH. ICAM-1 (intercellular adhesion molecule-1) gene transfection inhibits lymph node metastasis by human gastric cancer cells. Jpn J Cancer Res, 2000, 91(9):925-933.
5. Hallahan DE, Geng L, Shyr Y. Effects of intercellular adhesion molecule 1 (ICAM-1) null mutation on radiation-induced pulmonary fibrosis and respiratory insufficiency in mice. J Natl Cancer inst, 2002, 94(10): 733-741.
6.Rosette C, Roth RB, Oeth P, et al. Role of ICAM-1 in invasion of human breast cancer cells. Carcinogenesis, 2005, 26(5): 943-950.
7.Ogawa Y, Hirakawa K, Nakata B, et al. Expression of intercellular adhesion molecule-1 in invasive breast cancer reflects low growth potential, negative lymph node involvement, and good prognosis. Clin Cancer Res, 1998, 4(1): 31-36.
8.Komi J, Lassila O. Toremifene increases the expression of intercellular adhesion molecule-1 (ICAM-1) on MCF-7 breast cancer cells and Jurkat cells. Scand immunol, 2000, 51(1):73-78.
9.Van Seventer GA, Shimizu Y, Horgan KJ, et al. The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. J Immunol, 1990, 144(12): 4579-4586.
10.Makgoba MW, Sanders ME, Ginther Luce GE, et al. Functional evidence that intercellular adhesion molecule-1 (ICAM-1) is a ligand for LFA-1-dependent adhesion in T cell-mediated cytotoxicity. Eur J Immunol, 1988, 18(4): 637-640.
11.Schmidt RE, Bartley G, Levine H, et al. Functional characterization of LFA-1 antigens in the interaction of human NK clones and target cells. J Immunol, 1985,135(2): 1020-1025.
12.Regidor PA, Callies R, Regidor M, et al. Expression of the cell adhesion molecules ICAM-1 and VCAM-1 in the cytosol of breast cancer tissue, benign breast tissue and corresponding sera. Eur J Gynaecol Oncol, 1998, 19(4): 377-383.
13.Griffioen AW, Horst E, Heider KH,et a1. Expression of CD44 splice variants during lymphocyte activation and tumor progression. Caner Res, 1993, 53(20): 4754-4756.
14.Okamoto I, Tsuiki H, Kenyon LC, et al. Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. Am J Pathol, 2002, 160(2): 441-447.
15.Patrawala L, Calhoun T, Schneider-Broussard R, et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene, 2006, 25(12): 1696-1708.
16.Peterson RM, Yu Q, Stamenkovic I, et al. Perturbation of hyaluronan interactions by soluble CD44 inhibits growth of murine mammary carcinoma cells in ascites. Am J Pathol, 2000, 156(6): 2159-2l67.
17.Mulder JW,Kruyt PM,Sewnath M,et al. Colorectal cancer prognosis and expression of exon-V6-containing CD44 proteins.Lancet,1994, 344(8935) :1470-1472.
18.Ropponen KM, Eskelinen MJ, Lipponen PK, et a1. Expression of CD44 and variant proteins in human colorectal cancer and its relevance for prognosis. Scand J Gastroenterol, 1998, 33(3):301-309.
19.Herrlich P, Zoller M, Pals ST, et a1. CD44 splice variants: metastases meet lymphocytes. Immunol Today, 1993, 14(8): 395-399.
20.Kaufman M, Heider KH, Sinn HP et a1. CD44 isoforms in prognosis of breast cancer. Lancet, 1995, 345(8959): 1237.
21.Ladeda V, Aguirre Ghiso JA, Bal de Kier Joffer, et a1. Function and expression of CD44 during spreading, migration, and invasion of murine carcinoma cells. Exp Cell Res, 1998, 242(2): 515-527.
22.Kim ZG, Mehl C, Lorenz M, et al. Impact of laparoscopic CO2-insufflation on tumor-associated molecules in cultured colorectal cancer cells. Surg Endosc, 2002,16(8): 1182-6.
23.Ordemann J, Hoflich C, Braumann C, et al. Impact of pneumoperitoneum on expression of E-cadherin, CD44v6 and CD54 (ICAM-1) on HT-29 colon-carcinoma cell. Zentralbl Chir, 2005, 130(5): 405-409.
24.Moss M A, Zimmer S, Anderson KW. Role of metastatic potential in the adhesion of human breast cancer cells to endothelial monolayers. Anticancer Res, 2000, 20(3A): 1425-1433.
25.Abdel-Ghany M, Cheng HC, Elble RC, et a1. The breast cancer beta 4 integrin and endothelial human CLCA2 mediate lung metastasis. J Biol Chem, 2001, 276(27): 25438-25446.
1.McGahan JP, Browning PD, Brock JM, et al. Hepatic ablation using radiofrequency electrocautery. Invest Radiol, 1990, 25(3):267-270.
2.Noguchi M. Minimally invasive ablation technique in breast cancer treatment.Ann Srug Oncol,2002, 9(4):319-320.
3.Jeffrey SS, Birdwell RL, Ikeda DM et al. Radiofrequency ablation of breast cancer: First report of an emerging technology. Arch Surg,1999,134(10):1064-1068.
4.Fornage BD, Sneige N, Ross MI et al. Small (< or = 2-cm) breast cancer treated with US-guided radiofrequency ablation: feasibility study. Radiology, 2004, 231(1): 215-224.
5.Burak WE Jr, Agnese DM, Povoski SP, et al. Radiofrequency ablation of invasive breast carcinoma followed by delayed surgical excision. Cancer, 2003,98(7): 1369-1376.
6.Hayashi A H, Silver S F, van der Westhuizen N G, et al. Treatment of invasive breast carcinoma with ultrasound-guided radiofrequency ablation. Am J surg, 2003, 185(5): 429-435.
7.吴沛宏.论射频消融技术在肿瘤综合治疗中的作用.中华放射学杂志,20O2, 36(4):29.
8.Chen L, Bouley D, Yuh E, et al. Study of focused ultrasound tissue damage using MRI and histology. J Magn Reson Imaging, 1999, 10(2):146-153.
9. McDannold, Hynynen K, Wolf D et al. MRI evaluation of thermal ablation of tumors with focused ultrasound. J Magn Reson Imaging, 1998, 8(1):91-100.
10.Hynynen K, Pomeroy O, Smith DN, et al. MR imaging-guided focused ultrasound surgery of fibroadenomas in the breast: A feasibility study. Radiology, 2001,219(1): 176-185.
11.Wu F, Wang ZB, Cao YD, et al. A randomised clinical trial of high-intensity focused ultrasound ablation for the treatment of patients with localised breast cancer. Br J Cancer, 2003,89(12): 2227-2233.
12.Ruers TJ, Joosten J, Jager GJ, et al. Long-term results of treating hepatic colorectal metastases with cryosurgery. Br J Surg, 2001, 88(6): 844-849.
13.Rand RW, Rand RP, Eggerding F et al. Cryolumpectomy for carcinoma of the breast. Surg Gynecol Obstet, 1987, 165(5): 392-396.
14.Rabin Y, Julian TB, Olson P et al. Long-term follow-up post-cryosurgery in a sheep breast model.Cryobiology, 1999, 39(1):29-46.
15.Pfleiderer SO, Freesmeyer MG, Marx C et al. Cryotherapy of breast cancer under ultrasound guidance: Initial results and limitations. Eur Radiol,2002,12(12): 3009-3014.
16.Mumtaz H, Hall-Craggs MA, Wotherspoon A et al. Laser therapy for breast cancer: MR imaging and histopathologic correlation. Radiology, 1996,200(3): 651-658.
17.Harms SE. MR-guided minimally invasive procedures. Magn Reson Imaging Clin N Am, 2001, 9(2): 381-392, vii.Review.
18.Dowlatshahi K, Francescatti DS, Bloom KJ et al. Image-guided surgery of small breast cancers. Am J Surg, 2001, 182(4):419-425.
19.Ochsner M . Photodynamic therapy: the clinical perspective. Review on applications for control of diverse tumorous and non-tumorous diseases Arzneimittelforschung,1997,47(11): 1185-ll94.
20.Allison R, Mang T, Hewson G, el al. Photodynamic therapy for chest wall progression form breast carcinoma is an underutilized treatment modality.Cancer, 2001,91(1): 1-8.
21.黄卓正,李峻亨.现代激光医学.南宁:广西科技出版社,1996,105-ll5.
22.Webber J, Herman M, Kessel D, et a1. Photodynamic treatment of neoplastic lesions of the gastrointestinal tract.Langenbecks Arch Surg, 2000, 85(4):299-304.
23.Mang TS, Allison R, Hewson G, et a1. A phase II/III clinical study of tin ethyl etiopurpurin (Purlytin)-induced photodynamic therapy for the treatment of recurrent cutaneous metastatic breast cancer.Cancer J Sci Am, 1998,4(6): 378-384.
24.Hofmann GA, Dev SB. Electroporation therapy: a new approach for the treatment of head and neck cancer. IEEE Transactions on Biomedical Engineering, 1999,46(6):752-759.
25.Nathalie D, Edith S, Yogeshvar K, et a1.In vivo assessment of skin electroporatlon using square wave pulses.Journal of Controlled Release, 2002, 79(1-3):219-227.
26.Toru H, Hirofumi N, Yasuhiro O, et al. Enhancing effect of electric stimulation on cytotoxicity of anticancer agents against rat and human glioma cells. Brain Research Bulletin, 2000,51(5): 371-378..
27.Mir LM. herapeutic perspectives of in vivo cell electro- permeabilization. Bioelectrochemistry, 2000,53(1):1-10.
28.Garner H, Hofmann GA, Dev SB, et al.Electrochemotherapy: Transition from laboratory to the clinic. IEEE Engineering in Medicine and Biology, 1996, 15(6): 124-132.
29.杨玉氏, 权宽宏.电化学治疗晚期乳腺癌临床研究.陕西肿瘤医学. 2002, 10(1): 29-30.
30.Rebersek M, Cufer T, Cemazar M. Electrochemotherapy with cisplatin of cutaneous tumor lesions in breast cancer. Anticancer Drugs, 2004,15(6): 593-597.
31.Baez E, Huber A, Vetter M. Minimal invasive complete excision of benign breast tumors using a three-dimensional ultrasound-guided mammotome vacuum dvice. Ultrasound Obstet Gynecol, 2003, 21(3):267-271.
32.Rebersek M, Cufer T, Cemazar M. Electrochemotherapy with cisplatin of cutaneous tumor lesions in breast cancer. Antcancer Drugs, 2004,15(6): 593-597.
33.Morton D, Wen DR, Wong J, et al. Technical details of intraopetative lymphatic mapping for early stage melanoma. Arch Surg,1992,127(4):392- 399.
34.Cox C E, Pendas S, Cox J M, et al. Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg, 1998, 227(5):645-651.
35.White R L, Wilke L G. Update on the NSABP and ACOSOG breast cancer sentinel node trials. Am Surg, 2004, 70(5):420-424.
36.Reitsamer R, Peintinger F, Prokop E, et al.200 Sentinel lymph node biopsies without axillary lymph node dissection- no axillary recurrences after a 3-year follow-up.Br J, 2004, 90(8):1551-1554.
37.张嘉庆, 王殊.乳腺外科新技术的发展与展望. 中国普外基础与临床杂志, 2005,12(3):201-203.
38.Wilmot C, Watemberg S, Landau O, et al. Of balloon axilloscopy and avoidance of iatrogenic injury to the long thoracic nerve. Arch Surg, 1997,132(10):1121-1124.
39.Harder F, Zuber M, Kocher T, et al.Endoscopic surgery to the axilla-a substitute for conventional axillary clearnce ? Recent Results Cancer Res, 1998,152:180-189.
2. Hall-Craggs MA, Vaidya Js. Minimally invasive therapy for the treatment of breast tumours. Eur J Radiol, 2002, 42(1):52-57.
3. Singletary SE, Fornage BD, Sneige N, et al. Radiofrequency ablation of early-stage invasive breast tumors: an overview. Cancer J, 2002, 8(2): 177-180. Review.
4.骆成玉, 季晓昕, 张键等.乳腔镜腋窝淋巴结清扫的手术技术.中华外科杂志, 2005, 43(1): 21-24.
5.张嘉庆, 王殊.乳腺外科新技术的发展与展望. 中国普外基础与临床杂志, 2005,12(3):201-203.
6. Wilmot C, Watemberg S, Landau O, et al. Of balloon axilloscopy and avoidance of iatrogenic injury to the long thoracic nerve. Arch Surg, 1997, 132(10): 1121-1124.
7. Ishizuka B, Kudo Y, Amemiya A, et al. Plasma catecholamine responses during laparoscopic gynecologic surgery with CO_2 insufflation. J Am Assoc Gynecol Laparosc, 2000, 7(1): 37-43.
8. Ordemann J, Hoflich C, Braumann C, et al. Impact of pneumoperitoneum on expression of E-cadherin, CD44v6 and CD54 (ICAM-1) on HT-29 colon-carcinoma cell. Zentralbl Chir, 2005, 130(5): 405-409.
9. Kim ZG, Mehl C, Lorenz M, et al.Impact of laparoscopic CO_2-insufflation on tumor-associated molecules in cultured colorectal cancer cells. Surg Endosc, 2002, 16(8): 1182-6.
10.王强, 章建全, 蔡清萍.实时超声引导、监测下经皮微创旋切手术治疗乳房良性肿块. 外科理论与实践, 2005, 10(1): 104-105.
1.骆成玉, 季晓昕, 张键等.乳腔镜腋窝淋巴结清扫的手术技术.中华外科杂志, 2005, 43(1): 21-24.
2.Abu-Rafea B, Vilos GA, Vilos AG, et al. High-pressure laparoscopic entry does not adversely affect cardiopulmonary function in healthy women. J Minim Invasive Gynecol, 2005, 12(6): 475-479.
3.Stang CM, Hachenberg T. Is the pneumoperitoneum minimally invasive during laparoscopic colonic surgery? Zentralbl Chir, 2004, 129(3): 196-9.
4. Mottura AA. Tumescent technique for liposuction.Plast Reconstr Surg, 1994, 94(7): 1096-1097.
5.Brown SA, Lipschitz AH, Kenkel JM, et al. Pharmacokinetics and safety of epinephrine use in liposuction. Plast Reconstr Surg, 2004, 114(3):756-763; discussion 764-765.
6.Platt MS, Kohler LJ, Ruiz R, et al. Deaths associated with liposuction: case reports and review of the literature. J Forensic Sci, 2002, 47(1):205-207.
7.Suzanne F, Emering C, Wattienz A, et al. Axillary lymphadenectomy by lipo-aspiration and endoscopic picking. Apropos of 72 cases. Chirurgie, 1997, 122(2): 138-142.
8.Salvat J, Knopf JF, Ayoubi JM. Endoscopic exploration and lymph node sampling of the axilla. Preliminary findings of a randomized pilot study comparing clinical and anatomo-pathologic results of endoscopic axillary lymph node sampling with traditional surgical treatmen.Eur J Obstet Gynecol Reprod Biol, 1996, 70(2): 165-173.
9.Kamprath S, Bechler J, Kuhne-Heid R, et al. Endoscopic axillary lymphadenectomy without prior liposuction. Development of a technique and initial experience.Surg Endosc, 1999, 13(12): 1226-1229.
10.杭燕南, 主编. 当代麻醉学. 上海: 上海科学技术出版社, 2002, 877-886.
11.Bellantone R, Lombardi CP, Rubino F, et a1. Arterial PCO2 and cardiovascular function during endoscopic neck surgery with carbon dioxide insufflation.Arch Surg, 2001, 136(7): 822-827.
12. 晋云, 陈训如. 二氧化碳气腹对呼吸循环系统影响研究的新进展. 解放军医学杂志, 2002, 7: 647-648.
13.McIntyre RC Jr, Haenel JB, Moore FA, et a1.Cardiopulmonary effects of permissive hypercapnia in the management of adult respiratory distress syndrome. J Trauma, 1994, 37(3): 433-438.
14.Naude GP Bongard FS.Helium insufflation in laparoscopic surgery. Endose Surg Allied Technol, 1995, 3(4): 183-186.
15.Bongard FS, Pianim NA, Leighton TA et a1.Helium insufflation for laparoscopic operation. Surg Gyneco, 1993, 177(2): 140-145.
16.Cakan A, Cagirici U, Cikirikcioglu M, et a1.The histological effect of harmonic scalpel and electrocautery in lung resections.An experimental study in a rat model. J Cardiovasc Surg (Torino), 2004, 45(1): 63-65.
17.Epstein MR, Mayer JE Jr, Duncan BW.Use of an ultrasonic scalpel as an alternative to electrocautery in patients with pacemakers. Ann Thorac Surg, 1998, 65(6): 1802-1804.
18.Amaral JF.The experimental development of an ultrasonically activated scalpel for laparoscopic use. Surg Laparosc Endosc, 1996, 4(2): 92-99.
19. Swanstrom LL, Pennings JL.Laparoscopic control of short gastric vessels. J Am Coll Surg, l995, 181(4): 347-351.
20.Lumachi F, Burelli P, Basso SM, et al. Usefulness of ultrasound scissors in reducing serous drainage after axillary dissection for breast cancer: a prospective randomized clinical study. Am Surg, 2004, 70(1): 80-84.
21.Porter KA, O’Connor S, Rimm E, et al. Electrocautery as a factor in seroma formation following mastectomy. Am J Surg, 1998, 176(1): 8-11.
22.Epstein MR, Mayer JE Jr, Duncan BW.Use of an ultrasonic scalpel as an alternative to electrocautery in patients with pacemakers. Ann Thorac Surg, 1998, 65(6): 1802-1804.
23.Kuhn T, Santjohanser C, Koretz K, et al. Axilloscopy and endoscopic sentinel node detection in breast cancer patients. Surg Endosc, 2000, 14(6):573-577.
24.Developments in minimally invasive breast surgery-overview and our own experience: new diagnostic and therapeutic challenges in breast cancer. Gynakol Geburtshilfliche Rundsch, 2000, 40(1): 3-12.
1.Fondrinier E, Boisdron-Celle M, Chassevent A, et al. Experimental assessment of tumor growth and dissemination of a microscopic peritoneal carcinomatosis after CO_2 peritoneal insufflation or laparotomy. Sury Endosc, 2001, 15(8): 843-848.
2.Tominaga H, Ishiyama M, Ohseto F, et al.A water-soluble tetrazolium salt useful for colorimetric cell viability assay. Anal Commun, 1999, 36(2):47-50.
3.Petersen OW, Ronnov-Jessen L, Weaver VM, et al. Differentiation and cancer in the mammary gland: shedding light on an old dichotomy. Adv Cancer Res, 1998, 75: 135-61.
4.Thompson CB.Apoptosis in pathogenesis and treatment of disease. Science, 1995, 267(5203): 1456-1462.
5.Tamm I, Schriever F, Dorken B. Apoptosis: implications of basic research for clinical oncology. Lancet Oncol, 2001, 2(1): 33-42.
6.keane MM, Ettenberg SA, Lowrey GA, et al. Fas expression and function in normal and malignant breast cell lines. Cancer Res, 1996, 56(20): 4791-4798.
7.Shrode LD, Tapper H, Grinstein, et al. Role of intracellular pH in proliferation, transformation, and apoptosis. J Bioenerg Biomember, 1997, 29(4): 393-399.
8.Lagadic-Gossmann D, Huc L, Lecureur V. Alterations of intracellular pH homeostasis in apoptosis: origins and roles. Cell Death Differ, 2004, 11(9): 953-961.
9.Jacobi CA, Sabat R, Bohm B, et al. Pneumoperitoneum with carbon dioxide stimulates growth of malignant colonic cells. Surgery, 1997, 121(1): 72-78.
10.Smidt VJ, Singh DM, Hurteau JA, et al. Effect of carbon dioxide on human ovarian carcinoma cell growth. Am J Obstet Gyneco1, 2001,185(6): 1314-1317.
11.Zhong H, De Marzo AM, Laughner E, et a1. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res, 1999, 59(22): 5830-5835.
12.Garayoa M, Martinez A, Lee S, et a1. Hypoxia-inducible factor-1 (HIF-1) up-regulates adrenomedullin expression in human tumor cell lines during oxygen deprivation: a possible promotion mechanism of carcinogenesis. Mol Endocrinol,2000, 14(6): 848-862.
13.Tendler DS, Bao C, Wang T, et a1. Intersection of interferon and hypoxia signal transduction pathways in nitric oxide-induced tumor apoptosis.Cancer Res, 2001, 61(9): 3682-3688.
14.Harmey JH, Bouchier-Hayes D. Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy. BioEssays, 2002, 24(3): 280-283.
15.左仲, 鲁向明. 乳腺癌与Fas系统. 世界肿瘤杂志, 2004,3(3): 29l-293.
16.Schett G, Steiner CW, Groger M, et a1. Activation of Fas inhibits heat-induced activation of HSF1 and up-regulation of hsp70. FASEB J,1999, 13(8): 833-842.
17.von Reyher U, Strater J, Kittstein W, et al. Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis. Cancer Res , 1998 ,58(3):526-534.
18.Nambu Y, Hughes SJ, Rehemtulla A, et al. Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas. J Clin Invest, 1998, 101(5): 1102-1110.
19.Reimer T, Herrnring C, Koczan D,et al. FasL:Fas ratio--a prognostic factor in breast carcinomas. Cancer Res, 2000, 60(4): 822-828.
20.Mottolese M, Buglioni S, Bracalenti C, et a1. Prognostic relevance of altered Fas (CD95)-system in human breast cancer.Int J Cancer, 2000, 89(2): 127-132.
21.Botti C, Buglioni S, Benevolo M, et a1. Altered expression of FAS system is related to adverse clinical outcome in stage I-II breast cancer patients treated with adjuvant anthracycline-based chemotherapy. Clin Cancer Res, 2004, 10(4): 1360-1365.
22.Sheard MA, Vojtesek B, Janakova L, et a1. Up-regulation of Fas (CD95) in human p53wild-type cancer cells treated with ionizing radiation. Int J Cancer, 1997, 73(5): 757-762.
23.Danforth DN, Zhu Y. Conversion of Fas-resistant to Fas-sensitive MCF-7 breast cancer cells by the synergistic interaction of interferon-gamma and all-trans retinoic acid. Breast Cancer Res Treat, 2005, 94(1):81-91.
24.O’Connell J, Bennett MW, O'Sullivan GC, et al.The Fas counterattack: cancer as asite of immune privilege. Immunol Today, 1999, 20(1): 46-52.
25.Shiraki K, Tsuji N, Shioda T, et al. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci USA, 1997, 94(12): 6420-6425.
26.Eberl LP, Valdenaire O, Saintgiorgio V, et al. Endothelin receptor blockade potentiates FasL-induced apoptosis in rat colon carcinoma cells. Int J Cancer, 2000, 86(2): 182-187.
27.Mullauer L, Mosberger I, Grusch M et al. Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer. J Pathol, 2000,
190(1):20-30.
28.Cianga C, ianga P, Cozma L, et al.The significance of Fas/FasL molecular system in breast cancer. Rev Med Chir Soc Med Nat Iasi, 2004, 108(2): 440-444.
29.O'Connell J, Bennett MW, O’sullivan, et al. Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege. Clin Diagn Lab Immunol, 1999, 6(4): 457-463.
30.Muller M, Wilder S, Bannasch D, et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med, 1998, 188(11): 2033-2045.
31.Muschen M, Moers C, Warskulat U, et al. CD95 ligand expression as a mechanism of immune escape in breast cancer. Immunology, 2000, 99(1): 69-77.
32.Nagarkatti N, Davis BA. Tamoxifen induces apoptosis in Fas+ tumor cells by upregulating the expression of Fas ligand. Cancer Chemother Pharmacol, 2003, 51(4): 284-290.
33.Samli MM, Guler C, Demirbas M, et al.The effect of carbon dioxide pneumoretroperitoneum on free oxygen radicals in rabbit retroperitoneoscopy model. Surg Laparosc Endosc Percutan Tech.2004, 14(3): 153-6.
1.高进.癌的侵袭与转移. 第1版.北京: 北京医科大学, 中国协和医科大学联合出版社, 1996: 17-18.
2.Gulubova MV.Expression of cell adhesion molecules, their ligands and tumour necrosis factor alpha in the liver of patients with metastatic gastrointestinal carcinomas. Histochem J, 2002, 34(1-2): 67-77.
3.Polverini PJ. Cellular adhesion molecules. Newly identified mediators of angiogenesis. Am J Patho, 1996, 148(4): 1023-1029.
4.Sunami T, Yashiro M, Chung KH. ICAM-1 (intercellular adhesion molecule-1) gene transfection inhibits lymph node metastasis by human gastric cancer cells. Jpn J Cancer Res, 2000, 91(9):925-933.
5. Hallahan DE, Geng L, Shyr Y. Effects of intercellular adhesion molecule 1 (ICAM-1) null mutation on radiation-induced pulmonary fibrosis and respiratory insufficiency in mice. J Natl Cancer inst, 2002, 94(10): 733-741.
6.Rosette C, Roth RB, Oeth P, et al. Role of ICAM-1 in invasion of human breast cancer cells. Carcinogenesis, 2005, 26(5): 943-950.
7.Ogawa Y, Hirakawa K, Nakata B, et al. Expression of intercellular adhesion molecule-1 in invasive breast cancer reflects low growth potential, negative lymph node involvement, and good prognosis. Clin Cancer Res, 1998, 4(1): 31-36.
8.Komi J, Lassila O. Toremifene increases the expression of intercellular adhesion molecule-1 (ICAM-1) on MCF-7 breast cancer cells and Jurkat cells. Scand immunol, 2000, 51(1):73-78.
9.Van Seventer GA, Shimizu Y, Horgan KJ, et al. The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. J Immunol, 1990, 144(12): 4579-4586.
10.Makgoba MW, Sanders ME, Ginther Luce GE, et al. Functional evidence that intercellular adhesion molecule-1 (ICAM-1) is a ligand for LFA-1-dependent adhesion in T cell-mediated cytotoxicity. Eur J Immunol, 1988, 18(4): 637-640.
11.Schmidt RE, Bartley G, Levine H, et al. Functional characterization of LFA-1 antigens in the interaction of human NK clones and target cells. J Immunol, 1985,135(2): 1020-1025.
12.Regidor PA, Callies R, Regidor M, et al. Expression of the cell adhesion molecules ICAM-1 and VCAM-1 in the cytosol of breast cancer tissue, benign breast tissue and corresponding sera. Eur J Gynaecol Oncol, 1998, 19(4): 377-383.
13.Griffioen AW, Horst E, Heider KH,et a1. Expression of CD44 splice variants during lymphocyte activation and tumor progression. Caner Res, 1993, 53(20): 4754-4756.
14.Okamoto I, Tsuiki H, Kenyon LC, et al. Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. Am J Pathol, 2002, 160(2): 441-447.
15.Patrawala L, Calhoun T, Schneider-Broussard R, et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene, 2006, 25(12): 1696-1708.
16.Peterson RM, Yu Q, Stamenkovic I, et al. Perturbation of hyaluronan interactions by soluble CD44 inhibits growth of murine mammary carcinoma cells in ascites. Am J Pathol, 2000, 156(6): 2159-2l67.
17.Mulder JW,Kruyt PM,Sewnath M,et al. Colorectal cancer prognosis and expression of exon-V6-containing CD44 proteins.Lancet,1994, 344(8935) :1470-1472.
18.Ropponen KM, Eskelinen MJ, Lipponen PK, et a1. Expression of CD44 and variant proteins in human colorectal cancer and its relevance for prognosis. Scand J Gastroenterol, 1998, 33(3):301-309.
19.Herrlich P, Zoller M, Pals ST, et a1. CD44 splice variants: metastases meet lymphocytes. Immunol Today, 1993, 14(8): 395-399.
20.Kaufman M, Heider KH, Sinn HP et a1. CD44 isoforms in prognosis of breast cancer. Lancet, 1995, 345(8959): 1237.
21.Ladeda V, Aguirre Ghiso JA, Bal de Kier Joffer, et a1. Function and expression of CD44 during spreading, migration, and invasion of murine carcinoma cells. Exp Cell Res, 1998, 242(2): 515-527.
22.Kim ZG, Mehl C, Lorenz M, et al. Impact of laparoscopic CO2-insufflation on tumor-associated molecules in cultured colorectal cancer cells. Surg Endosc, 2002,16(8): 1182-6.
23.Ordemann J, Hoflich C, Braumann C, et al. Impact of pneumoperitoneum on expression of E-cadherin, CD44v6 and CD54 (ICAM-1) on HT-29 colon-carcinoma cell. Zentralbl Chir, 2005, 130(5): 405-409.
24.Moss M A, Zimmer S, Anderson KW. Role of metastatic potential in the adhesion of human breast cancer cells to endothelial monolayers. Anticancer Res, 2000, 20(3A): 1425-1433.
25.Abdel-Ghany M, Cheng HC, Elble RC, et a1. The breast cancer beta 4 integrin and endothelial human CLCA2 mediate lung metastasis. J Biol Chem, 2001, 276(27): 25438-25446.
1.McGahan JP, Browning PD, Brock JM, et al. Hepatic ablation using radiofrequency electrocautery. Invest Radiol, 1990, 25(3):267-270.
2.Noguchi M. Minimally invasive ablation technique in breast cancer treatment.Ann Srug Oncol,2002, 9(4):319-320.
3.Jeffrey SS, Birdwell RL, Ikeda DM et al. Radiofrequency ablation of breast cancer: First report of an emerging technology. Arch Surg,1999,134(10):1064-1068.
4.Fornage BD, Sneige N, Ross MI et al. Small (< or = 2-cm) breast cancer treated with US-guided radiofrequency ablation: feasibility study. Radiology, 2004, 231(1): 215-224.
5.Burak WE Jr, Agnese DM, Povoski SP, et al. Radiofrequency ablation of invasive breast carcinoma followed by delayed surgical excision. Cancer, 2003,98(7): 1369-1376.
6.Hayashi A H, Silver S F, van der Westhuizen N G, et al. Treatment of invasive breast carcinoma with ultrasound-guided radiofrequency ablation. Am J surg, 2003, 185(5): 429-435.
7.吴沛宏.论射频消融技术在肿瘤综合治疗中的作用.中华放射学杂志,20O2, 36(4):29.
8.Chen L, Bouley D, Yuh E, et al. Study of focused ultrasound tissue damage using MRI and histology. J Magn Reson Imaging, 1999, 10(2):146-153.
9. McDannold, Hynynen K, Wolf D et al. MRI evaluation of thermal ablation of tumors with focused ultrasound. J Magn Reson Imaging, 1998, 8(1):91-100.
10.Hynynen K, Pomeroy O, Smith DN, et al. MR imaging-guided focused ultrasound surgery of fibroadenomas in the breast: A feasibility study. Radiology, 2001,219(1): 176-185.
11.Wu F, Wang ZB, Cao YD, et al. A randomised clinical trial of high-intensity focused ultrasound ablation for the treatment of patients with localised breast cancer. Br J Cancer, 2003,89(12): 2227-2233.
12.Ruers TJ, Joosten J, Jager GJ, et al. Long-term results of treating hepatic colorectal metastases with cryosurgery. Br J Surg, 2001, 88(6): 844-849.
13.Rand RW, Rand RP, Eggerding F et al. Cryolumpectomy for carcinoma of the breast. Surg Gynecol Obstet, 1987, 165(5): 392-396.
14.Rabin Y, Julian TB, Olson P et al. Long-term follow-up post-cryosurgery in a sheep breast model.Cryobiology, 1999, 39(1):29-46.
15.Pfleiderer SO, Freesmeyer MG, Marx C et al. Cryotherapy of breast cancer under ultrasound guidance: Initial results and limitations. Eur Radiol,2002,12(12): 3009-3014.
16.Mumtaz H, Hall-Craggs MA, Wotherspoon A et al. Laser therapy for breast cancer: MR imaging and histopathologic correlation. Radiology, 1996,200(3): 651-658.
17.Harms SE. MR-guided minimally invasive procedures. Magn Reson Imaging Clin N Am, 2001, 9(2): 381-392, vii.Review.
18.Dowlatshahi K, Francescatti DS, Bloom KJ et al. Image-guided surgery of small breast cancers. Am J Surg, 2001, 182(4):419-425.
19.Ochsner M . Photodynamic therapy: the clinical perspective. Review on applications for control of diverse tumorous and non-tumorous diseases Arzneimittelforschung,1997,47(11): 1185-ll94.
20.Allison R, Mang T, Hewson G, el al. Photodynamic therapy for chest wall progression form breast carcinoma is an underutilized treatment modality.Cancer, 2001,91(1): 1-8.
21.黄卓正,李峻亨.现代激光医学.南宁:广西科技出版社,1996,105-ll5.
22.Webber J, Herman M, Kessel D, et a1. Photodynamic treatment of neoplastic lesions of the gastrointestinal tract.Langenbecks Arch Surg, 2000, 85(4):299-304.
23.Mang TS, Allison R, Hewson G, et a1. A phase II/III clinical study of tin ethyl etiopurpurin (Purlytin)-induced photodynamic therapy for the treatment of recurrent cutaneous metastatic breast cancer.Cancer J Sci Am, 1998,4(6): 378-384.
24.Hofmann GA, Dev SB. Electroporation therapy: a new approach for the treatment of head and neck cancer. IEEE Transactions on Biomedical Engineering, 1999,46(6):752-759.
25.Nathalie D, Edith S, Yogeshvar K, et a1.In vivo assessment of skin electroporatlon using square wave pulses.Journal of Controlled Release, 2002, 79(1-3):219-227.
26.Toru H, Hirofumi N, Yasuhiro O, et al. Enhancing effect of electric stimulation on cytotoxicity of anticancer agents against rat and human glioma cells. Brain Research Bulletin, 2000,51(5): 371-378..
27.Mir LM. herapeutic perspectives of in vivo cell electro- permeabilization. Bioelectrochemistry, 2000,53(1):1-10.
28.Garner H, Hofmann GA, Dev SB, et al.Electrochemotherapy: Transition from laboratory to the clinic. IEEE Engineering in Medicine and Biology, 1996, 15(6): 124-132.
29.杨玉氏, 权宽宏.电化学治疗晚期乳腺癌临床研究.陕西肿瘤医学. 2002, 10(1): 29-30.
30.Rebersek M, Cufer T, Cemazar M. Electrochemotherapy with cisplatin of cutaneous tumor lesions in breast cancer. Anticancer Drugs, 2004,15(6): 593-597.
31.Baez E, Huber A, Vetter M. Minimal invasive complete excision of benign breast tumors using a three-dimensional ultrasound-guided mammotome vacuum dvice. Ultrasound Obstet Gynecol, 2003, 21(3):267-271.
32.Rebersek M, Cufer T, Cemazar M. Electrochemotherapy with cisplatin of cutaneous tumor lesions in breast cancer. Antcancer Drugs, 2004,15(6): 593-597.
33.Morton D, Wen DR, Wong J, et al. Technical details of intraopetative lymphatic mapping for early stage melanoma. Arch Surg,1992,127(4):392- 399.
34.Cox C E, Pendas S, Cox J M, et al. Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg, 1998, 227(5):645-651.
35.White R L, Wilke L G. Update on the NSABP and ACOSOG breast cancer sentinel node trials. Am Surg, 2004, 70(5):420-424.
36.Reitsamer R, Peintinger F, Prokop E, et al.200 Sentinel lymph node biopsies without axillary lymph node dissection- no axillary recurrences after a 3-year follow-up.Br J, 2004, 90(8):1551-1554.
37.张嘉庆, 王殊.乳腺外科新技术的发展与展望. 中国普外基础与临床杂志, 2005,12(3):201-203.
38.Wilmot C, Watemberg S, Landau O, et al. Of balloon axilloscopy and avoidance of iatrogenic injury to the long thoracic nerve. Arch Surg, 1997,132(10):1121-1124.
39.Harder F, Zuber M, Kocher T, et al.Endoscopic surgery to the axilla-a substitute for conventional axillary clearnce ? Recent Results Cancer Res, 1998,152:180-189.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |